Amolyt plans to use the proceeds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly.
Amolyt plans to use the proceeds to advance its pipeline of therapeutics for rare endocrine and related disorders, including AZP-3601, now known as eneboparatide, for the treatment of hypoparathyroidism, and AZP-3813 for the treatment of acromegaly.